Cargando…
Revisiting IgG Antibody Reactivity to Epstein-Barr Virus in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Its Potential Application to Disease Diagnosis
Infections by the Epstein-Barr virus (EBV) are often at the disease onset of patients suffering from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). However, serological analyses of these infections remain inconclusive when comparing patients with healthy controls (HCs). In particular,...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9263839/ https://www.ncbi.nlm.nih.gov/pubmed/35814774 http://dx.doi.org/10.3389/fmed.2022.921101 |
_version_ | 1784742837396439040 |
---|---|
author | Sepúlveda, Nuno Malato, João Sotzny, Franziska Grabowska, Anna D. Fonseca, André Cordeiro, Clara Graça, Luís Biecek, Przemyslaw Behrends, Uta Mautner, Josef Westermeier, Francisco Lacerda, Eliana M. Scheibenbogen, Carmen |
author_facet | Sepúlveda, Nuno Malato, João Sotzny, Franziska Grabowska, Anna D. Fonseca, André Cordeiro, Clara Graça, Luís Biecek, Przemyslaw Behrends, Uta Mautner, Josef Westermeier, Francisco Lacerda, Eliana M. Scheibenbogen, Carmen |
author_sort | Sepúlveda, Nuno |
collection | PubMed |
description | Infections by the Epstein-Barr virus (EBV) are often at the disease onset of patients suffering from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). However, serological analyses of these infections remain inconclusive when comparing patients with healthy controls (HCs). In particular, it is unclear if certain EBV-derived antigens eliciting antibody responses have a biomarker potential for disease diagnosis. With this purpose, we re-analyzed a previously published microarray data on the IgG antibody responses against 3,054 EBV-related antigens in 92 patients with ME/CFS and 50 HCs. This re-analysis consisted of constructing different regression models for binary outcomes with the ability to classify patients and HCs. In these models, we tested for a possible interaction of different antibodies with age and gender. When analyzing the whole data set, there were no antibody responses that could distinguish patients from healthy controls. A similar finding was obtained when comparing patients with non-infectious or unknown disease trigger with healthy controls. However, when data analysis was restricted to the comparison between HCs and patients with a putative infection at their disease onset, we could identify stronger antibody responses against two candidate antigens (EBNA4_0529 and EBNA6_0070). Using antibody responses to these two antigens together with age and gender, the final classification model had an estimated sensitivity and specificity of 0.833 and 0.720, respectively. This reliable case-control discrimination suggested the use of the antibody levels related to these candidate viral epitopes as biomarkers for disease diagnosis in this subgroup of patients. To confirm this finding, a follow-up study will be conducted in a separate cohort of patients. |
format | Online Article Text |
id | pubmed-9263839 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92638392022-07-09 Revisiting IgG Antibody Reactivity to Epstein-Barr Virus in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Its Potential Application to Disease Diagnosis Sepúlveda, Nuno Malato, João Sotzny, Franziska Grabowska, Anna D. Fonseca, André Cordeiro, Clara Graça, Luís Biecek, Przemyslaw Behrends, Uta Mautner, Josef Westermeier, Francisco Lacerda, Eliana M. Scheibenbogen, Carmen Front Med (Lausanne) Medicine Infections by the Epstein-Barr virus (EBV) are often at the disease onset of patients suffering from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). However, serological analyses of these infections remain inconclusive when comparing patients with healthy controls (HCs). In particular, it is unclear if certain EBV-derived antigens eliciting antibody responses have a biomarker potential for disease diagnosis. With this purpose, we re-analyzed a previously published microarray data on the IgG antibody responses against 3,054 EBV-related antigens in 92 patients with ME/CFS and 50 HCs. This re-analysis consisted of constructing different regression models for binary outcomes with the ability to classify patients and HCs. In these models, we tested for a possible interaction of different antibodies with age and gender. When analyzing the whole data set, there were no antibody responses that could distinguish patients from healthy controls. A similar finding was obtained when comparing patients with non-infectious or unknown disease trigger with healthy controls. However, when data analysis was restricted to the comparison between HCs and patients with a putative infection at their disease onset, we could identify stronger antibody responses against two candidate antigens (EBNA4_0529 and EBNA6_0070). Using antibody responses to these two antigens together with age and gender, the final classification model had an estimated sensitivity and specificity of 0.833 and 0.720, respectively. This reliable case-control discrimination suggested the use of the antibody levels related to these candidate viral epitopes as biomarkers for disease diagnosis in this subgroup of patients. To confirm this finding, a follow-up study will be conducted in a separate cohort of patients. Frontiers Media S.A. 2022-06-24 /pmc/articles/PMC9263839/ /pubmed/35814774 http://dx.doi.org/10.3389/fmed.2022.921101 Text en Copyright © 2022 Sepúlveda, Malato, Sotzny, Grabowska, Fonseca, Cordeiro, Graça, Biecek, Behrends, Mautner, Westermeier, Lacerda and Scheibenbogen. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Medicine Sepúlveda, Nuno Malato, João Sotzny, Franziska Grabowska, Anna D. Fonseca, André Cordeiro, Clara Graça, Luís Biecek, Przemyslaw Behrends, Uta Mautner, Josef Westermeier, Francisco Lacerda, Eliana M. Scheibenbogen, Carmen Revisiting IgG Antibody Reactivity to Epstein-Barr Virus in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Its Potential Application to Disease Diagnosis |
title | Revisiting IgG Antibody Reactivity to Epstein-Barr Virus in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Its Potential Application to Disease Diagnosis |
title_full | Revisiting IgG Antibody Reactivity to Epstein-Barr Virus in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Its Potential Application to Disease Diagnosis |
title_fullStr | Revisiting IgG Antibody Reactivity to Epstein-Barr Virus in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Its Potential Application to Disease Diagnosis |
title_full_unstemmed | Revisiting IgG Antibody Reactivity to Epstein-Barr Virus in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Its Potential Application to Disease Diagnosis |
title_short | Revisiting IgG Antibody Reactivity to Epstein-Barr Virus in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Its Potential Application to Disease Diagnosis |
title_sort | revisiting igg antibody reactivity to epstein-barr virus in myalgic encephalomyelitis/chronic fatigue syndrome and its potential application to disease diagnosis |
topic | Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9263839/ https://www.ncbi.nlm.nih.gov/pubmed/35814774 http://dx.doi.org/10.3389/fmed.2022.921101 |
work_keys_str_mv | AT sepulvedanuno revisitingiggantibodyreactivitytoepsteinbarrvirusinmyalgicencephalomyelitischronicfatiguesyndromeanditspotentialapplicationtodiseasediagnosis AT malatojoao revisitingiggantibodyreactivitytoepsteinbarrvirusinmyalgicencephalomyelitischronicfatiguesyndromeanditspotentialapplicationtodiseasediagnosis AT sotznyfranziska revisitingiggantibodyreactivitytoepsteinbarrvirusinmyalgicencephalomyelitischronicfatiguesyndromeanditspotentialapplicationtodiseasediagnosis AT grabowskaannad revisitingiggantibodyreactivitytoepsteinbarrvirusinmyalgicencephalomyelitischronicfatiguesyndromeanditspotentialapplicationtodiseasediagnosis AT fonsecaandre revisitingiggantibodyreactivitytoepsteinbarrvirusinmyalgicencephalomyelitischronicfatiguesyndromeanditspotentialapplicationtodiseasediagnosis AT cordeiroclara revisitingiggantibodyreactivitytoepsteinbarrvirusinmyalgicencephalomyelitischronicfatiguesyndromeanditspotentialapplicationtodiseasediagnosis AT gracaluis revisitingiggantibodyreactivitytoepsteinbarrvirusinmyalgicencephalomyelitischronicfatiguesyndromeanditspotentialapplicationtodiseasediagnosis AT biecekprzemyslaw revisitingiggantibodyreactivitytoepsteinbarrvirusinmyalgicencephalomyelitischronicfatiguesyndromeanditspotentialapplicationtodiseasediagnosis AT behrendsuta revisitingiggantibodyreactivitytoepsteinbarrvirusinmyalgicencephalomyelitischronicfatiguesyndromeanditspotentialapplicationtodiseasediagnosis AT mautnerjosef revisitingiggantibodyreactivitytoepsteinbarrvirusinmyalgicencephalomyelitischronicfatiguesyndromeanditspotentialapplicationtodiseasediagnosis AT westermeierfrancisco revisitingiggantibodyreactivitytoepsteinbarrvirusinmyalgicencephalomyelitischronicfatiguesyndromeanditspotentialapplicationtodiseasediagnosis AT lacerdaelianam revisitingiggantibodyreactivitytoepsteinbarrvirusinmyalgicencephalomyelitischronicfatiguesyndromeanditspotentialapplicationtodiseasediagnosis AT scheibenbogencarmen revisitingiggantibodyreactivitytoepsteinbarrvirusinmyalgicencephalomyelitischronicfatiguesyndromeanditspotentialapplicationtodiseasediagnosis |